Skip to main content

Table 1 Clinical and pathological features of patient group

From: Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT

Feature

 

Total

Gleason score

7

7 (26.9%)

26 (100%)

8

9 (34.6%)

9

8 (30.8%)

10

2 (7.7%)

ISUP score

1

0

26 (100%)

2

2 (7.7%)

3

5 (19.2%)

4

9 (34.6%)

5

10 (38.5%)

Risk classification

High risk

29 (90.6%)

31 (100%)

Intermediate risk

2 (9.4%)

Low risk

0

Definitive therapy to prostate gland

None

41 (87.2%)

47 (100%)

Total prostatectomy

3 (6.4%)

Radiotherapy

3 (6.4%)

Serum PSA value at diagnosis

Mean ± standart deviation (minimum–maximum)

510.72 ± 1127.49 (0.22–5476)